Table 4B. Placebo and. LXS Groups at Baseline and 12 Months.
Characteristics | n | Baseline | 12 Months | P1 | P2 |
---|---|---|---|---|---|
Age, yr | |||||
Placebo | 6 | 13.3 ± 1.1 | 14.3 ± 1.1 | ||
LXS | 8 | 12.6 ± 1.7 | 13.7 ± 1.8 | ||
MRS | |||||
Calf Choline, % | |||||
Placebo | 6 | 0.09 ± 0.01 | 0.09 ± 0.02 | 0.785 | 0.034 |
LXS | 8 | 0.09 ± 0.02 | 0.12 ± 0.04 | 0.005 | |
Calf Lipid fraction, % | |||||
Placebo | 6 | 4.87 ± 1.97 | 5.83 ± 2.80 | 0.001 | 0.636 |
LXS | 8 | 3.87 ± 1.02 | 5.01 ± 1.08 | <0.001 | |
Liver lipid, % | |||||
Placebo | 6 | 5.01 ± 5.57 | 6.60 ± 6.52 | 0.100 | 0.993 |
LXS | 8 | 7.98 ± 8.54 | 9.60 ± 4.66 | 0.591 |